Vitamin D supplementation after the menopause
Pérez-López, Faustino R. ; Chedraui, Peter ; Pilz, Stefan
Resumen: The purpose of this review was to assess recent evidence regarding the effects of low vitamin D levels on some highly prevalent clinical conditions of postmenopausal women. We reviewed and selected recent literature regarding menopause-related conditions associated with vitamin D deficiency and interventions to manage them. Low circulating 25-hydroxyvitamin D (25(OH)D) levels related to menopause are linked to diet, lifestyle, changes in body composition, insulin sensitivity, and reduced physical activity. Vitamin D supplementation increases serum 25(OH)D levels while normalizing parathyroid hormone and bone markers, and in women with serum 25(OH)D levels below 10 ng/ml supplementation may improve bone mineral density. Low vitamin D status has been associated with the metabolic syndrome, high triglyceride levels, and low high-density lipoprotein cholesterol levels. When compared with placebo, vitamin D supplementation may lower the risk of the metabolic syndrome, hypertriglyceridemia, and hyperglycemia. There is an inverse relationship between fat mass and serum 25(OH)D levels and, therefore, the dosage of supplementation should be adjusted according to the body mass index. Although vitamin D supplementation may improve glucose metabolism in prediabetic subjects, data regarding muscle strength are conflictive. There is evidence that vitamin D over-treatment, to reach extremely high circulating 25(OH)D levels, does not result in better clinical outcomes. The identification and treatment of vitamin D deficiency in postmenopausal women may improve their general health and health outcomes. Vitamin D supplementation should preferably be based on the use of either cholecalciferol or calcifediol.
Idioma: Inglés
DOI: 10.1177/2042018820931291
Año: 2020
Publicado en: Therapeutic Advances in Endocrinology and Metabolism 11 (2020), 1-13
ISSN: 2042-0188
Factor impacto JCR: 3.565 (2020)
Categ. JCR: ENDOCRINOLOGY & METABOLISM rank: 87 / 145 = 0.6 (2020) - Q3 - T2
Factor impacto SCIMAGO: 0.889 - Endocrinology, Diabetes and Metabolism (Q2)
Tipo y forma: Article (Published version)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.
Exportado de SIDERAL (2021-09-02-09:49:09)
Visitas y descargas
Idioma: Inglés
DOI: 10.1177/2042018820931291
Año: 2020
Publicado en: Therapeutic Advances in Endocrinology and Metabolism 11 (2020), 1-13
ISSN: 2042-0188
Factor impacto JCR: 3.565 (2020)
Categ. JCR: ENDOCRINOLOGY & METABOLISM rank: 87 / 145 = 0.6 (2020) - Q3 - T2
Factor impacto SCIMAGO: 0.889 - Endocrinology, Diabetes and Metabolism (Q2)
Tipo y forma: Article (Published version)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. Exportado de SIDERAL (2021-09-02-09:49:09)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles
Record created 2020-08-11, last modified 2021-09-02